News und Analysen
NanoString to Release Second Quarter 2021 Operating Results and Host Conference Call on Wednesday, August 4, 2021
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release second quarter 2021
Humana Hiring up to 200 Seasonal Positions in Louisville
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is looking to hire up to 200 seasonal Enrollment Representatives in and around Louisville.
Humana’s Medicare
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021. Management will hold a conference call
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021. Management will hold a conference call
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2021, the Compensation Committee (the “Compensation Committee”) of Puma’s Board of Directors approved
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
ICON plc, (NASDAQ: ICLR) (“ICON”) today announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement to the U.S. Prescribing Information
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Novocure (NASDAQ: NVCR) today announced final results from its phase 2 pilot HEPANOVA trial in liver cancer testing the safety and efficacy of Tumor Treating Fields (TTFields) together with
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Bronson Healthcare Partners With Acadia Healthcare to Build New Behavioral Health Hospital to Serve Southwest Michigan
Bronson Healthcare and Acadia Healthcare Company announced today that they have formed a joint venture to build a 96-bed inpatient behavioral health facility in Battle Creek, Michigan. Together
Acadia Healthcare Forms Joint Venture with Bronson Health to Build a New Behavioral Health Facility in Southwest Michigan
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Bronson Healthcare, one of Michigan’s leading, integrated healthcare systems. The new
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006120/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
Humana Ranked No. 1 Among Health Insurers for Customer Experience
Humana ranked No. 1 among Health Insurers for customer experience (CX) quality in Forrester’s proprietary 2021 US CX Index™ survey. The ranking was based on responses from more than 85,000 US
TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software
Waters Corporation (NYSE:WAT) today introduced TRIOS AutoPilot software from its TA Instruments Division for its thermal analyzer product line. The software helps laboratory staff using TA’s
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the third quarter of fiscal year 2021, the period ended May 31, 2021, after the close of the
LivaNova to Host Conference Call for Second Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m
BOIRON : PROJECTED TIMETABLE OF THE NEXT PUBLICATIONS AND EVENTS 2022
The projected timetable of the next publications and events for the year 2022 is the following one:
Publications Date of publication (after market closing) Information meetings
Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition
Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals (Clovis’ licensing partner and
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute
Waters Corporation (NYSE:WAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that the first UK patient has been